Cargando…

Gene therapy for spinal muscular atrophy: the benefit–cost profile

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343260/ https://www.ncbi.nlm.nih.gov/pubmed/34386755 http://dx.doi.org/10.1016/j.eclinm.2021.101065

Ejemplares similares

Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)

Gene therapy for spinal muscular atrophy: Solomon's consensus in Covid times
por: Zafeiriou, Dimitrios
Publicado: (2020)

Spinal muscular atrophy, pediatric virology and gene therapy: A challenge of modern weakness and hope
por: Darras, Basil T., et al.
Publicado: (2018)

Interventions for spinal muscular atrophy: an impetus for newborn screening
Publicado: (2021)

Gene therapy for spinal muscular atrophy: the Qatari experience
por: Ali, Hossamaldein Gaber, et al.
Publicado: (2021)

Onasemnogene Abeparvovec for Spinal Muscular Atrophy: The Costlier Drug Ever
por: Mahajan, Rajiv
Publicado: (2019)

Nusinersen and Spinal Muscular Atrophies: Where are we in 2020?
por: Khadilkar, Satish V., et al.
Publicado: (2020)

Spinal muscular atrophy
por: D'Amico, Adele, et al.
Publicado: (2011)

Commentary: Current Status of Gene Therapy for Spinal Muscular Atrophy
por: Rossoll, Wilfried, et al.
Publicado: (2022)

Emerging therapies and challenges in spinal muscular atrophy
por: Farrar, Michelle A., et al.
Publicado: (2017)

Splice-Switching Therapy for Spinal Muscular Atrophy
por: Meijboom, Katharina E., et al.
Publicado: (2017)

Estimation Of The Quality Of Life Benefits Associated With Treatment For Spinal Muscular Atrophy
por: Lloyd, Andrew J, et al.
Publicado: (2019)

Costs of Illness of Spinal Muscular Atrophy: A Systematic Review
por: Landfeldt, Erik, et al.
Publicado: (2021)

Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England
por: Weidlich, Diana, et al.
Publicado: (2023)

Cost-effectiveness analysis of gene-based therapies for patients with spinal muscular atrophy type I in Australia
por: Wang, Tianjiao, et al.
Publicado: (2022)

Spinal Muscular Atrophy and Ependymoma
por: Albakr, Aishah, et al.
Publicado: (2017)

Risdiplam for spinal muscular atrophy
Publicado: (2022)

Antisense-based therapy for the treatment of spinal muscular atrophy
por: Rigo, Frank, et al.
Publicado: (2012)

miRNA in spinal muscular atrophy pathogenesis and therapy
por: Magri, Francesca, et al.
Publicado: (2017)

Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders
por: Jablonka, Sibylle, et al.
Publicado: (2022)

Gene therapy-based strategies for spinal muscular atrophy—an Asia-Pacific perspective
por: Farrar, Michelle A., et al.
Publicado: (2023)

Metabolic Dysfunction in Spinal Muscular Atrophy
por: Deguise, Marc-Olivier, et al.
Publicado: (2021)

Update on Biomarkers in Spinal Muscular Atrophy
por: Pino, Megan G, et al.
Publicado: (2021)

Modeling Spinal Muscular Atrophy in Drosophila
por: Chang, Howard Chia-Hao, et al.
Publicado: (2008)

Carrier screening for spinal muscular atrophy
por: Prior, Thomas W.
Publicado: (2008)

Androgens in spinal and bulbar muscular atrophy
Publicado: (2012)

Spinal Muscular Atrophy: The Treatment Approved
por: Tabet, Rabih, et al.
Publicado: (2017)

Advances in spinal muscular atrophy therapeutics
por: Parente, Valeria, et al.
Publicado: (2018)

Euglycemic Ketoacidosis in Spinal Muscular Atrophy
por: Stoimenis, Dimitrios, et al.
Publicado: (2019)

Onasemnogene abeparvovec for spinal muscular atrophy
Publicado: (2022)

Mitochondrial Dysfunction in Spinal Muscular Atrophy
por: Zilio, Eleonora, et al.
Publicado: (2022)

Editorial: Advances in spinal muscular atrophy
por: Sun, Jianli
Publicado: (2023)

Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US
por: Thokala, Praveen, et al.
Publicado: (2020)

Healthcare Utilization, Costs of Care, and Mortality Among Patients With Spinal Muscular Atrophy
por: Tan, Hiangkiat, et al.
Publicado: (2019)

Healthcare Utilization, Costs of Care, and Mortality Among Patients With Spinal Muscular Atrophy
por: Tan, Hiangkiat, et al.
Publicado: (2019)

Systematic review and meta-analysis determining the benefits of in vivo genetic therapy in spinal muscular atrophy rodent models
por: Chilcott, Ellie M., et al.
Publicado: (2021)

Alternative Splicing Role in New Therapies of Spinal Muscular Atrophy
por: Lejman, Jan, et al.
Publicado: (2021)

Therapy Development for Spinal Muscular Atrophy in SMN Independent Targets
por: Tsai, Li-Kai
Publicado: (2012)

Editorial: Spinal Muscular Atrophy: Evolutions and Revolutions of Modern Therapy
por: Finkel, Richard S., et al.
Publicado: (2020)

Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies
por: Pane, Marika, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mepl81s312lol97791f6knphvm